Catalogue information
Signatures facsimile. Piece by name. Depreciation by perforation and / or stamping. Schering Corporation was first established in the late 1800s as the U.S. subsidiary of Schering AG, a German-based pharmaceutical and chemical company. In 1928, Schering Corporation was incorporated in New York City and in 1935 in New Jersey. Schering Corporation initially offered a modest but promising line of pharmaceutical products to U.S. consumers, which led to steady growth and a rapid expansion of facilities. The 1940s proved to be a key decade in the history of the company, as it evolved from a European-based company with U.S. operations into a truly American enterprise. Schering Corporation had been nationalized by the U.S. government during World Wars I and II, and in 1952 the company passed into the private sector. For Schering, the 1950s and 1960s were characterized by continued growth, attributable to research and development and acquisition activities. Schering Corporation grew to become a global research-based pharmaceutical firm, and in 1971, merged with Plow Inc., a worldwide manufacturer of consumer products, to create Schering-Plow Corporation. The merger proved successful, as only a decade later the company's sales had grown fourfold. In the 1980s and 1990s, Schering-Plow refined its focus on four key therapeutic areas and continued to excel at innovative approaches to treating disease. New research technologies acquired during this time quickly became important tools in Schering-Plow's research program, enabling the company to achieve important pharmaceutical advances and significant breakthroughs in antihistamines, corticosteroids, antibiotics, anti-infectives and antiviral products. Current products include: Clarinex, Tinactin, and the Dr. Scholl's footcare and Coppertone suncare lines.
This text has been translated automatically from Dutch
Click here for the original text